Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is filed by Addex Therapeutics Ltd., a foreign private issuer headquartered in Geneva, Switzerland, for the month of April 2026. The filing, dated April 21, 2026, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1) into the company's active registration statements (Form F-3 and Form S-8).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report acts as a conduit for a press release rather than a standalone financial statement. No financial data is presented within the body of this Form 6-K.
Material Changes
The document does not detail specific material changes in financial performance or operations compared to prior periods. It references the incorporation of a press release but does not summarize the content of that release within the filing text itself.
Guidance, Outlook, and Risks
The filing includes standard risk factor disclosures, stating that the company's business faces significant risks that could materially adversely affect its financial condition and growth prospects. It directs investors to the Annual Report on Form 20-F for the year ended December 31, 2024, filed on May 15, 2025, for a comprehensive list of risk factors. The document also contains a disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated outcomes due to various uncertainties.
Key Facts for Investor Verification
- Verify the content of the press release dated April 21, 2026 (Exhibit 99.1), as the specific news or updates are not summarized in this filing text.
- Review the Annual Report on Form 20-F for the year ended December 31, 2024, for detailed risk factors and historical financial data.
- Confirm the status of the company's registration statements (Form F-3 No. 333-291644 and Form S-8 Nos. 333-255124 and 333-272515) into which this report is incorporated.
- Note that no financial metrics are disclosed in this specific document; investors must refer to the attached exhibit or other filings for quantitative data.